Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2016 | Biomarkers and lung cancer: Future status

Keith Kerr • 12 Apr 2016
ELCC 2016
Lung Cancer

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Keith Kerr, BSc, MB ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, United Kingdom, summarises future research directions for biomarkers in the management of patients with lung cancer, including the opportunities and challenges associated testing for multiple biomarkers and liquid biopsies.

More from Keith Kerr

2:55
Challenges of biomarker testing in the UK
Keith Kerr • 26 Apr 2023
3:32
Biomarker testing for ADCs
Keith Kerr • 27 Apr 2023
2:16
Pathology training in the molecular era
Keith Kerr • 24 Jan 2019
2:14
Pathology practice, an ever-changing field as more biomarkers emerge
Keith Kerr • 24 Jan 2019

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals